

of cases with loss with or without ALK fusion. **Table S5.** P-values for comparisons of the frequencies of chromosome aberrations in all chromosome arms between tumours with or without ALK fusion. **Table S6.** Number of cases with copy number gain or loss at selected loci with or without ALK fusion. **Table S7.** Significance of the differences in frequencies of copy number changes (gains and losses) between tumours with or without ALK fusion.

Additional file 2: Figure S1. Mutation rates for EGFR, TP53 and KRAS according to cumulative smoking are shown. EGFR and KRAS mutations were only detected among ALK fusion negative cases, so ALK fusion positive cases were not included in the analysis. Note the gradually decrease in EGFR mutation rate with increase in cumulative smoking. KRAS mutations were detected only among smokers.

Additional file 3: Figure S2. Comparisons of copy number alteration rates at selected loci with or without ALK fusion. Note that 5p15.33 including *TERT* shows the highest gain both in ALK fusion positive and negative tumours, the frequencies being identical.

Competing interest

The authors have no potential conflicts of interest.

Authors' contributions

HN, MK, SO, HM and YI designed the study. HN, KT, KI, NM, HM and YI performed pathological and/or genomic diagnosis of tumors. HN, MK, MS and SO obtained microarray data and carried out bioinformatics analysis. HN and KN analyzed mutations. YS, SO and YI collected samples and/or provided detailed clinical data of patients. HN and YI drafted the manuscript. All authors read and approved the final manuscript.

Authors' information

HM has found ALK fusion in lung cancer with own developed cDNA library. MK, MS and SO detected genes responsible for hematological disorders through same algorithm with this study. CNAG/AsCAR. KT has created a novel diagnostic method to detect ALK fusion positive lung cancer. YI has found characteristic pathological features of ALK positive cancer.

Acknowledgements

We would like to express my gratitude to Satoko Baba for assistance in sample preparation and Yuki Takano for secretary work. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, from Japan Society for the Promotion of Science, grants from the Ministry of Health, Labour and Welfare, the Japan Science and Technology Agency, and the Smoking Research Foundation.

Author details

¹Division of Pathology, The Cancer Institute, Ariake 3-8-31, Koutou-ku, Tokyo 135-8550, Japan. ²Pathology Project for Molecular Targets, The Cancer Institute, Ariake 3-8-31, Koutou-ku, Tokyo 135-8550, Japan. ³Thoracic Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koutou-ku, Tokyo 135-8550, Japan. ⁴Cancer Genomics Project, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8656, Japan. ⁵Department of Pediatrics, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8656, Japan. ⁶Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8656, Japan. ⁷Division of Functional Genomics, Jichi Medical University, Tochigi 329-0498, Japan.

Received: 6 April 2012 Accepted: 18 December 2012

Published: 5 January 2013

References

1. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Canc Inst* 2005, **97**:339-346.
2. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell

lung cancers in relation to smoking history. *Cancer Res* 2007, **67**:5667-5672.

3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007, **448**:561-566.
4. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res* 2008, **14**:4275-4283.
5. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H: Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. *Clin Cancer Res* 2008, **14**:6618-6624.
6. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H: KIF5B-ALK, a novel fusion oncokinasase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res* 2009, **15**:3143-3149.
7. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol* 2008, **3**:13-17.
8. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol* 2009, **22**:508-515.
9. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K, Tsuda H: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. *Am J Surg Pathol* 2011, **5**:1226-1234.
10. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainer J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafate AJ, Camidge DR: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol* 2011, **12**:1004-1012.
11. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010, **363**:1693-1703.
12. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafate AJ: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. *J Thorac Oncol* 2011, **6**:942-946.
13. Osada H, Takahashi T: Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. *Oncogene* 2002, **21**:7421-7434.
14. Järvinen AK, Autio R, Kilpinen S, Saarela M, Leivo I, Grénman R, Mäkitie AA, Monni O: High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. *Gene Chromosome Canc* 2008, **47**:500-509.
15. Lo KC, Stein LC, Panzarella JA, Cowell JK, Hawthorn L: Identification of genes involved in squamous cell carcinoma of the lung using synchronized data from DNA copy number and transcript expression profiling analysis. *Lung Cancer* 2008, **59**:315-331.
16. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y: RET, ROST, and ALK Fusions in Lung Cancer. *Nat Med* 2012, **18**:378-381.
17. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y: Iet-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. *Lung Cancer* 2007, **58**:392-396.

18. Travis WD, Elisabeth B, Muller-Hermelink HK, Harris CC: *Pathology and Genetics of Tumours of the Lung, Pleural, Thymus and Heart*. Lyon: IARC press; 2004.
19. AJCC: *Cancer Staging Manual*. 6th edition; 2002:167–177. Chapter 19; Lung - original pages.
20. Ishikawa Y, Furuta R, Miyoshi T, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E: Loss of heterozygosity and the smoking index increase with decrease in differentiation of lung adenocarcinomas: etiologic implications. *Cancer Lett* 2002, **187**:47–51.
21. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S: A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. *Cancer Res* 2005, **65**:6071–6079.
22. Ogawa S, Nannya Y, Yamamoto G: Genome-wide copy number analysis on GeneChip platform using copy number analyzer for affymetrix GeneChip 2.0 software. *Meth Mol Biol* 2007, **396**:185–206.
23. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, Koeffler HP, Ogawa S: Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. *Am J Hum Genet* 2007, **81**:114–126.
24. Danner BC, Gerdes JS, Jung K, Sander B, Enders C, Liersch T, Seipelt R, Gutenber A, Gunawan B, Schöndube FA, Füzesi L: Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases. *Canc Genet* 2011, **204**:122–128.
25. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhir M, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, et al: Characterizing the cancer genome in lung adenocarcinoma. *Nature* 2007, **450**:893–898.
26. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K, Lee J, Choi YL, Sato M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD, Pollack JR: Genomic profiling identifies TTF1 as a lineage-specific oncogene amplified in lung cancer. *Oncogene* 2008, **27**:3635–3640.
27. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y: Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. *J Thorac Oncol* 2011, **6**:15–20.
28. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastrì AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG: Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. *J Thorac Oncol* 2011, **6**:28–31.
29. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. *J Thorac Oncol* 2009, **4**:22–29.
30. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J: A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. *Gene Chromosome Canc* 2010, **49**:342–352.
31. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB P, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liao L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA: The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. *Proc Natl Acad Sci USA* 2009, **106**:9435–9440.
32. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature* 2007, **448**:595–599.
33. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, Asakura Y, Akatsuka M, Hayashi Y, Mori H, Igarashi T, Kurokawa M, Chiba S, Mori S, Ishikawa Y, Okamoto K, Tobinai K, Nakagawa H, Nakahata T, Yoshino T, Kobayashi Y, Ogawa S: Frequent inactivation of A20 in B-cell lymphomas. *Nature* 2009, **459**:712–716.
34. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, Tamura A, Honda H, Sakata-Yanagimoto M, Kumano K, Oda H, Yamagata T, Takita J, Gotoh N, Nakazaki K, Kawamata N, Onodera M, Nobuyoshi M, Hayashi Y, Harada H, Kurokawa M, Chiba S, Mori H, Ozawa K, Omine M, Hirai H, Nakauchi H, Koeffler HP, Ogawa S: Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. *Nature* 2009, **460**:904–908.
35. Ninomiya H, Nomura K, Satoh Y, Okumura S, Nakagawa K, Fujiwara M, Tsuchiya E, Ishikawa Y: Genetic instability in lung cancer: concurrent analysis of chromosomal, mini- and microsatellite instability and loss of heterozygosity. *Br J Cancer* 2006, **94**:1485–1491.
36. Yoshino I, Fukuyama S, Kameyama T, Shikada Y, Oda S, Maehara Y, Sugimachi K: Detection of loss of heterozygosity by high-resolution fluorescent system in non-small cell lung cancer: association of loss of heterozygosity with smoking and tumor progression. *Chest* 2003, **123**:545–550.
37. Yohena T, Yoshino I, Takenaka T, Ohba T, Kouso H, Osoegawa A, Hamatake M, Oda S, Kuniyoshi Y, Maehara Y: Relationship between the loss of heterozygosity and tobacco smoking in pulmonary adenocarcinoma. *Oncol Res* 2007, **16**:333–339.
38. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanière P, Brennan P, Boffetta P, Zaridze DG, Hainaut P: TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. *Cancer Res* 2005, **65**:5076–5083.
39. Gazdar AF, Shigematsu H, Herz J, Minna JD: Mutations and addiction to EGFR: the Achilles 'heel' of lung cancers? *Trends Mol Med* 2004, **10**:481–486.
40. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. *Pharmacol Ther* 1999, **82**:241–250.
41. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Gazdar AF CL, Bunn PA Jr, Hirsch FR: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. *J Clin Oncol* 2005, **23**:5007–5018.
42. Varella-Garcia M, Mitsudomi T, Yatabe Y: EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. *J Thorac Oncol* 2009, **4**:318–325.
43. Pugh TJ, Bebb G, Barclay L, Sutcliffe M, Fee J, Salski C, O'Connor R, Ho C, Murray N, Melosky B, English J, Vielkind J, Horsman D, Laskin JJ, Marra MA: Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. *BMC Canc* 2007, **7**:128.
44. Blons H, Pallier K, Le Corre D, Danel C, Tremblay-Gravel M, Houdayer C, Fabre-Guillevin E, Riquet M, Dessen P, Laurent-Puig P: Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. *BMC Med Genom* 2008, **1**:25.
45. Zhang A, Zheng C, Lindvall C, Hou M, Ekedahl J, Lewensohn R, Yan Z, Yang X, Henriksson M, Blennow E, Nordenskjöld M, Zetterberg A, Björkholm M, Gruber A, Xu D: Frequent amplification of the telomerase reverse transcriptase gene in human tumors. *Cancer Res* 2000, **60**:6230–6235.
46. Saretzki G, Petersen S, Petersen I, Köblle K, von Zglinicki T: hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. *Cancer Lett* 2002, **176**:81–91.
47. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM: Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. *Canc Genet Cytogenet* 2008, **182**:1–11.
48. Hsiung CA, Lan Q, Hong YC, Chen CJ, Hosgood HD, Chang IS, Chatterjee N, Brennan P, Wu C, Zheng W, Chang GC, Wu T, Park JY, Hsiao CF, Kim YH, Shen H, Seow A, Yeager M, Tsai YH, Kim YT, Chow WH, Guo H, Wang WC, Sung SW, Hu Z, Chen KY, Kim JH, Chen Y, Huang L, Lee KM, et al: The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. *PLoS Genet* 2010, **6**:e1001051.
49. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, McLaughlin J, Shepherd F, Montpetit A, Narod S, Krokan HE, Skorpén F, Elvestad MB, Vatten L, Njølstad

- I, Axelsson T, Chen C, Goodman G, Barnett M, Loomis MM, *et al.* Lung cancer susceptibility locus at 5p15.33. *Nat Genet* 2008, **40**:1404–1406.
50. Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varela-Garcia M: Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. *Cancer* 2012, **118**:4486–4494.

doi:10.1186/1471-2407-13-8

Cite this article as: Ninomiya *et al.*: Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. *BMC Cancer* 2013 **13**:8.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit





ELSEVIER

Original contribution

Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript^{☆,☆☆}

Kaori Tsuji DVM^{a,*}, Yuichi Ishikawa MD, PhD^b, Tetsuo Imamura MD^a^aDivision of Surgical Pathology, Teikyo University Hospital, Tokyo 173-8606, Japan^bDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan

Received 20 January 2011; revised 2 May 2011; accepted 4 May 2011

Keywords:

Alveolar soft part sarcoma;
Differential diagnosis;
ASPSCR1-TFE3 fusion transcript;
RT-PCR;
Immunohistochemistry

Summary The diagnosis of alveolar soft part sarcoma is commonly based on characteristic histology and distinctive periodic acid–Schiff–positive crystals; however, the characteristic crystals may not always be observed, rendering the diagnosis difficult. Three important characteristics of alveolar soft part sarcoma, the presence of ASPSCR1-TFE3 fusion transcript, nuclear immunoreactivity for TFE3, and immunoreactivity for monocarboxylate transporter 1 and CD147, have recently been reported. To identify the best marker for alveolar soft part sarcoma in formalin-fixed, paraffin-embedded tissues, we evaluated the sensitivity and specificity of the detection of the ASPSCR1-TFE3 fusion transcript along with the immunoreactivity for TFE3 and CD147 in 24 alveolar soft part sarcomas and 23 non-alveolar soft part sarcoma tumors, including 5 granular cell tumors, 5 paragangliomas, 3 clear cell sarcomas, and 10 clear cell renal cell carcinomas. The ASPSCR1-TFE3 fusion transcript was detected in 24 of 24 alveolar soft part sarcomas (7 type 1, 17 type 2), and TFE3 immunoreactivity was observed in 22 of 24 alveolar soft part sarcomas. In non-alveolar soft part sarcoma tumors, the ASPSCR1-TFE3 fusion transcript was not detected; however, the TFE3 immunoreactivity was observed in 2 of 5 granular cell tumors. CD147 immunoreactivity was demonstrated in 20 of 24 alveolar soft part sarcomas, 3 of 5 granular cell tumors, and 8 of 10 clear cell renal cell carcinomas. Our results demonstrate that the most sensitive marker of alveolar soft part sarcoma was the presence of the ASPSCR1-TFE3 fusion transcript. Thus, detection of the ASPSCR1-TFE3 fusion transcript was considered applicable for formalin-fixed, paraffin-embedded tissues with superior sensitivity as compared with TFE3 immunohistochemical staining. In alveolar soft part sarcomas with unusual locations or histology, we consider that the detection of the ASPSCR1-TFE3 fusion transcript would be the highly effective diagnostic technique. © 2011 Elsevier Inc. All rights reserved.

Abbreviations: ASPS, alveolar soft part sarcoma; RCC, renal cell carcinoma; RT-PCR, reverse transcription polymerase chain reaction.

[☆] Sources of funding: None.

^{☆☆} Disclosure of conflict of interests: None.

* Corresponding author. Division of Surgical Pathology, Teikyo University Hospital, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan.

E-mail address: danchan@med.teikyo-u.ac.jp (K. Tsuji).

1. Introduction

Alveolar soft part sarcoma (ASPS) is a rare tumor that occurs mostly in young adults, generally in the soft tissues of the extremities. ASPS has a distinctive histology with a nest-like or organoid pattern separated by fibrovascular septa [1]. Although these features are usually diagnostic, the diagnosis of ASPS may become difficult when ASPS occurs in an unusual location, such as in the lung, stomach, retroperitoneum, and female genital tract [2]. This is, in part, because a number of more common tumors such as granular cell tumor, paraganglioma, clear cell sarcoma, and metastatic clear cell renal cell carcinoma (RCC) mimic histologic features of ASPS. The discrimination of ASPS from these tumors is critical because the management strategy differs markedly for each tumor type. Cytoplasmic crystals identified with periodic acid-Schiff staining with diastase digestion or under electron microscopy are the classical histologic features of ASPS [3]. However, such typical crystals are observed only in 22% to 80% of ASPS cases [1,4-6]. Although numerous immunohistochemical studies have been reported, a specific marker that can confirmatively diagnose ASPS has not been found thus far [2].

Recently, a tumor-specific fusion transcript for ASPS, ASPSCR1-TFE3, has been identified by the analysis of snap-frozen tumor materials, and 2 different types of fusion transcripts, that is, types 1 and 2, have been reported [7]. Subsequently, aberrant nuclear immunoreactivity for TFE3 has been reported in formalin-fixed, paraffin-embedded ASPS; however, TFE3 immunoreactivity has also been observed in 9 types of non-ASPS tumors, including high-grade myxofibrosarcoma, malignant peripheral nerve sheath tumor, granular cell tumor, chordoma, adrenal cortical carcinoma, urothelial carcinoma, distal bile duct carcinoma, pediatric RCC, and perivascular epithelioid cell neoplasm [8,9]. TFE3 immunoreactivity is highly sensitive and specific for ASPS; however, this specificity was not mutually exclusive. More recently, in a subset of perivascular epithelioid cell tumor, gene fusion involving the *TFE3* gene has been reported [10,11]. Strong immunoreactivities for monocarboxylate transporter 1 and its interacting partner CD147 have been reported for the cytoplasm of ASPS tumor cells. Unlike the positive immunoreactivity in the cytoplasmic membrane seen for many tumors, the cytoplasmic granular positivity for CD147 in the ASPS is suggested to be related to precrystalline cytoplasmic granules [12]. Based on the unique expression pattern of CD147 in ASPS, we speculated that immunoreactivity of CD147 makes it a possible diagnostic marker of ASPS, and therefore, we examined this possibility in the current study. Moreover, no comparative study has evaluated the ability of the above-mentioned 3 markers in clarifying the differential diagnosis for ASPS. Therefore, to determine the optimal method for identifying ASPS in formalin-fixed, paraffin-embedded tissues, we assessed the sensitivity and specificity of the

detection of the ASPSCR1-TFE3 fusion transcript along with the immunoreactivity for TFE3 and CD147.

2. Materials and methods

2.1. Tumor specimens

Twenty-four ASPS specimens that had been embedded in paraffin were obtained from Japanese patients, of which 20 specimens were selected from the files of the authors (T.I. and Y.I.) and 4 specimens were provided by the Division of Diagnostic Pathology of the Keio University Hospital. These samples consisted of 22 primary tumors, 1 lung metastatic tumor, and 1 local recurrent tumor (Table 1). Twenty-three non-ASPS tumors, comprising 5 granular cell tumors, 5 paragangliomas, 3 clear cell sarcomas, and 10 clear cell RCCs (grades 1 and 2; 5 specimens each), were selected from the files of the Division of Surgical Pathology of the Teikyo University Hospital. Almost all the specimens were fixed in 10% to 20% formalin, and only 1 specimen (ASPS-9) was fixed in ethanol. Hematoxylin and eosin-stained slides were reviewed, and the original diagnosis was confirmed. Each 3- μ m-thick serial section was used for immunohistochemical staining.

Table 1 Clinical data and results of immunohistochemical staining and RT-PCR in 24 ASPS samples

Case no.	Age (y)	Sex	Site	Source	TFE3	CD147	Fusion type
1	15	F	Thigh	P	++	++	1
2	33	M	Thigh	P	++	++	2
3	15	M	Thigh	P	++	++	1
4	61	F	Thigh	P	++	+	1
5	20	M	Thigh	P	++	+	2
6	14	M	Upper arm	P	++	+	2
7	28	M	Lower leg	P	++	++	1
8	13	F	Shoulder	P	++	+	1
9	19	M	Thigh	P	+	+	2
10	20	F	Thigh	P	++	++	2
11	53	F	Thigh	P	++	++	2
12	45	M	Lower leg	M	++	++	2
13	30	M	Thigh	P	++	-	1
14	37	M	Thigh	P	++	+	1
15	28	M	Thigh	P	++	-	2
16	24	F	Thigh	Rec	++	++	2
17	15	M	Thigh	P	++	+	2
18	29	F	Thigh	P	++	+	2
19	46	M	Back	P	-	++	2
20	44	F	Upper arm	P	++	-	2
21	13	F	Chest wall	P	++	+	2
22	19	M	Shoulder	P	-	+	2
23	16	F	Thigh	P	+	-	2
24	37	M	Thigh	P	++	+	2

Abbreviations: F, female; M, male; P, primary tumor; M, metastatic tumor; Rec, recurrent tumor.

Table 2 Primer sequences and expected product size (bp)

First PCR	Outer forward	ASPL		5'-AAAGAAGTCCAAGTCGGGCCA-3' ^a	
	Outer reverse	TFE 3	Type 1	5'-CCTTGACTACTGTACACATCAAGC-3'	132
			Type 2	5'-CATTGTAAGTGGACTCCAGGC-3'	137
Nested PCR	Inner forward	ASPL		5'-AAGTCCAAGTCGGGCCAGG-3'	
	Inner reverse	TFE 3	Type 1	5'-CAGATTCCCTGACACAGGCA-3'	105
			Type 2	5'-GACTCCAGGCTGATGATCTC-3'	122
H3 histone family 3A	Forward			5'-CGAGAAATTGCTCAGGACTT-3'	
	Reverse			5'-TACACGTTTGGCATGGAT-3'	138

^a This sequence was cited from Ladanyi et al [7].

2.2. Immunohistochemistry

Immunohistochemical staining was performed with the EnVision Detection System (Dako, Carpinteria, CA). Sections were pretreated in the microwave oven for 10 minutes in 10 mmol/L citrate acid (pH 6.0) for epitope retrieval. After cooling for 30 minutes, the sections were treated with 0.3% hydrogen peroxide to eliminate endogenous peroxidase activity. Primary antibodies, TFE3 (1:600 dilution, polyclonal, P-16, sc-5958; Santa Cruz Biotechnology, Santa Cruz, CA), and CD147 (1:100 dilution, monoclonal, clone HIM6; Research Diagnostics, Inc, Flanders, NJ) were used. The diluted antibody was applied overnight at 4°C, and the sections were developed with 3,3'-diaminobenzidine and counterstained with Mayer hematoxylin. We used a labeled polymer (Simple Stain MAX-PO [G]; Nichirei, Tokyo, Japan) for the immunohistochemical staining of TFE3 because the polymer supplied by EnVision Detection System was unavailable for goat polyclonal antibodies.

TFE3 nuclear immunoreactivity was graded on the basis of the intensity of labeling as follows: no staining (-), weak staining (+), or moderate to strong staining (++). Cytoplasmic discrete granular staining for CD147 was scored on the basis of the frequency of immunoreactive granules as follows: no staining (-), rare staining (+), or moderate to numerous staining (++). Membrane and diffuse cytoplasmic staining for CD147 were disregarded because it is known that CD147 immunoreactivity is observed in the membrane and cytoplasm of many tumors [13].

2.3. Reverse transcription polymerase chain reaction

Total RNA was extracted from paraffin-embedded tumor tissues. Five 10- μ m sections from each tissue block were digested in buffer (20 mmol/L Tris-HCl, pH 8.0, 20 mmol/L EDTA, 2% sodium dodecyl sulfate) containing 10- μ L of 100 mg/mL proteinase K at 55°C overnight. RNA was extracted using ISOGEN (Nippon Gene, Toyama, Japan) according to the manufacturer's instructions. The extracted RNA was then purified by phenol saturated with water. Approximately 5 μ g of RNA was reverse transcribed into complementary DNA using a random primer and SuperScript II (Invitrogen, San Diego,

CA). The quality of RNA was assessed by amplification of H3 histone family 3A expressed ubiquitously. The amplification for the ASPSCR1-TFE3 fusion transcript was performed using Ex Taq Hot Start Version (TaKaRa, Ohtsu, Shiga, Japan); subsequently, nested polymerase chain reaction (PCR) was performed using AmpliTaq Gold (Applied Biosystems, Branchburg, NJ). Primer sequences and setting are shown in Table 2 and Fig. 1, respectively. Amplification of the first PCR consisted of denaturation at 95°C for 20 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 1 minute. After 50 cycles, 0.5 μ L of the first PCR product was used as a template for the nested PCR. Touchdown PCR as nested PCR was performed, with the annealing temperature reduced by 0.5°C per cycle from 60°C to 55°C, followed by 10 further cycles at 55°C. As a positive control for the ASPSCR1-TFE3 fusion transcript, RNA extracted from 2 frozen specimens, ASPS-1 for type 1 and ASPS-2 for type 2, were used. Furthermore, a reaction mixture of reagents devoid of template complementary DNA was included in each reverse transcription (RT) PCR procedure. The PCR products were electrophoresed in 2.5% agarose gel with ethidium bromide and sequenced using an automated sequencing system (PRISM 310; Applied Biosystems, Foster City, CA).

3. Results

3.1. Immunohistochemical findings

Nuclear immunoreactivity for the TFE3 protein was observed in 22 of 24 ASPS specimens as shown in Table 1




Fig. 1 Schematic diagram of the ASPSCR1-TFE3 fusion product. Sequences (105 bp long) are only found in the type 2 fusion product. Relative dimensions are approximate. Arrows indicate first (upper part) or nested (lower part) primers.

and Fig. 2. Twenty of 22 TFE3-positive ASPSs demonstrated moderate to strong (++) nuclear labeling (Fig. 2B), whereas the other 2 ASPSs demonstrated weak (+) nuclear




Fig. 2 TFE3 immunoreactivity in ASPS. Typical histology of ASPS showing well-defined nests of cells with abundant cytoplasm in case ASPS-6 (A; hematoxylin and eosin stain). Nuclear immunoreactivity for TFE3 showing intensive staining (++) in case ASPS-5 (B) and weak reactivity (+) in case ASPS-9 (C).




Fig. 3 TFE3 immunoreactivity in granular cell tumor. Characteristic histology of granular cell tumor showing rounded and polygonal cells with abundant granular cytoplasm (A; hematoxylin and eosin stain). Nuclear immunoreactivity for TFE3 showing moderate staining (++) (B).

labeling. One of the ASPS specimens that showed weak (+) labeling was weakly positive in only a small biopsy specimen, whereas the wide resection specimen from the same case tested negative. The other ASPS that was weakly positive (+) was the ASPS sample fixed in ethanol (Fig. 2C). In non-ASPS tumors, 2 of 5 granular cell tumors only showed nuclear immunoreactivity for TFE3 (Fig. 3). Sensitivity and specificity of TFE3 immunohistochemistry for ASPS detection were 92% and 92%, respectively. With regard to CD147 immunoreactivity, 20 of the 24 ASPSs demonstrated cytoplasmic discrete granular staining that appeared as spherical globules or polygonal inclusions (Fig. 4A, B). Similar granular inclusions for CD147 were observed in 3 of 5 granular cell tumors (Fig. 4C, D) and in 8 of 10 clear cell RCCs (Fig. 4E, F). Granular cell tumors showed small and coarse granular labeling (Fig. 4D), whereas the clear cell RCCs showed spherical globules or polygonal inclusions (Fig. 4F). ASPS and clear cell RCC grade 2 samples




Fig. 4 Immunohistochemical staining for CD147. Cytoplasmic discrete granular staining in cases ASPS-1 (A) and ASPS-5 (B). Granular cell tumor (C; hematoxylin and eosin stain) and small and coarse granular labeling for CD147 (D). Clear cell RCC grade 2 (E; hematoxylin and eosin stain) and CD147 immunoreactivity (F). Clear cell RCC grade 2 bears a strong resemblance to ASPS.

showed a strikingly similar immunoreactive pattern. Sensitivity and specificity of CD147 immunohistochemistry for ASPS detection were 83% and 52%, respectively.

3.2. Molecular findings

In all the 24 ASPSs, the ASPSCR1-TFE3 fusion transcript was detected by RT-PCR (Fig. 5). The fusion transcripts were composed of 7 type 1 and 17 type 2 transcripts as shown in Table 1. The ASPSCR1-TFE3 fusion transcript was not detected in any of the 23 non-ASPS tumors despite sufficient amplification of the internal control H3 histone family 3A. Sensitivity and specificity of ASPSCR1-TFE3 fusion transcript for ASPS detection were 100% for both.

4. Discussion

In the present study, we have shown that the most sensitive marker of ASPS is the presence of the ASPSCR1-TFE3 fusion transcript (100% sensitivity), although immunohistochemistry for TFE3 is highly sensitive (92% sensitivity). The RT-PCR assay designed for formalin-fixed, paraffin-embedded samples can be considered the most powerful tool currently available for identifying ASPS.

Immunohistochemical staining for TFE3 is now often performed for identifying ASPS occurring in unusual locations, such as in the breast, urinary bladder, and uterine cervix [14-16], because TFE3 immunoreactivity in ASPS

was first described [8]. This is reasonable because of its high sensitivity, specificity, and practicality. However, on the basis of studies investigating much wider spectra of tumors than our present study, the specificity of TFE3 immunohistochemistry is not necessarily high. In fact, 9 different types of tumors with TFE3 immunoreactivity are known [8,9]. Strong TFE3 immunoreactivity has been reported in a subset of perivascular epithelioid cell tumor and RCCs due to genetic alterations involving *TFE3* [8,10,11,17]. These results indicate that TFE3-positive findings do not always lead to a confirmed diagnosis. For the accurate diagnosis of ASPS, careful investigation would be required, including clinical findings, histologic features, identification of characteristic crystals, immunohistochemical staining for melanocytic marker (to differentiate from perivascular epithelioid cell tumor), and immunoreactivity for S-100 protein (to differentiate from granular cell tumor) [1,11].

The sensitivity of TFE3 immunohistochemistry is also problematic. In this study, 2 ASPS specimens (ASPS-19 and ASPS-22) did not show any TFE3 immunoreactivity. We believe that these negative results were false negative because the ASPSCR1-TFE3 fusion transcript was detected in these ASPSs. Because overexpression of the TFE3 protein in ASPS is probably caused by translocation including the *TFE3* gene [8], the detection of the ASPSCR1-TFE3 fusion transcript suggests that the negative TFE3 immunoreactivity result was false negative. Two other ASPS samples (ASPS-9 and ASPS-23) showed weak immunoreactivity for TFE3. This may be due to inadequate fixation or other unfavorable tissue conditions and variations in quality between different batches




Fig. 5 RT-PCR analysis for ASPSCR1-TFE3 fusion transcripts. The upper panel shows that the fusion transcript was detected in ASPS samples, whereas non-ASPS tumors and the sample without template (N) tested negative. The lower panel shows that the internal control was detectable in all the samples. The brighter band indicates 125 bp. Abbreviations: M, 25-bp ladder marker; GC, granular cell tumor; R1 and R2, samples of clear cell RCC grade 2.

of polyclonal antibodies [17]. These findings indicate that TFE3 immunoreactivity is not entirely sensitive for ASPS; thus, a negative result cannot conclusively exclude ASPS.

Our present results demonstrated that the detection of the ASPSCR1-TFE3 fusion transcript in ASPS was more highly sensitive than TFE3 immunoreactivity. However, whether the paraffin-based RT-PCR assay is a more sensitive method than immunohistochemistry remains an unresolved question. Generally, it is known that the RNA extracted from paraffin-embedded material may have been subject to degradation; therefore, the levels of the fusion transcript may be below the detection threshold [18]. It is possible that the positive results obtained in this study were a result of the primer design, which ensured a short PCR product. We hypothesize that the shorter PCR product probably leads to higher rates of detection in RT-PCR using paraffin-embedded material. To verify the validity of this hypothesis, we compared the size of the PCR product and the detection rate of the ASPSCR1-TFE3 fusion transcript in 7 studies that analyzed the ASPSCR1-TFE3 fusion transcript in paraffin-embedded material [6,19-24]. We thus found a close correlation between the PCR product size and the detection rate of the ASPSCR1-TFE3 fusion transcript (Table 3). These findings are in accordance with the conclusions of Williams et al [21],

who reported that RT-PCR techniques designed for application on paraffin-embedded material are highly sensitive and specific in detecting the ASPSCR1-TFE3 fusion transcript. An in-depth study that investigated the suitability of RNA-based analysis using various archival fixed specimens has demonstrated that the API2-MALT1 fusion transcript recognized in mucosal-associated lymphoid tissue lymphoma is amenable to RT-PCR if the fragment length is less than 150 base pairs (bp) [25]. These findings provide evidence that the PCR product size greatly affects the detection rate of the fusion transcript. In the present study, a PCR product measuring 237 bp was detected in the ASPS-9 sample that was fixed in ethanol (unpublished observations). It indicates that type 2 ASPSCR1-TFE3 fusion transcript of ASPS-9 was amplified by type 1 primer set (Fig. 1; Table 2). Ethanol fixation may be involved in low degradation or high extraction of RNA. It is known that prolonged storage of paraffin block-embedded tissues has some negative effects in RT-PCR [26]; however, 1 of our samples that was stored for 26 years, the longest storage period in the present study, was feasible for use in RT-PCR.

Furthermore, it is possible that the nested PCR performed in the present study contributed to the high detection rate of the ASPSCR1-TFE3 fusion transcript, because the increased

Table 3 Size of PCR product and detection rate of ASPSCR1-TFE3 fusion transcript

Product size (bp)			Total cases	Detected cases	Detection rate (%)	References
	Type 1	Type 2				
	116	127	6	6	100	19
	116	128	5	5	100	20
	120	130	1	1	100	6
	120	130	13	13	100	21
	126	130	1	1	100	22
First PCR	132	137	24	24	100	Present study
Nested PCR	105	122				
First PCR	190	310	16	11	69	23
Nested PCR	138	243				
	195	300	33	13	39	24

cycle number for nested PCR probably promoted an amplification of the ASPSCR1-TFE3 fusion transcript from the degraded RNA. The nested PCR in this study was originally intended to exclude certain unexpected bands recognized in non-ASPS tumors. It was highly effective for obtaining specific amplified products and, in addition, probably promoted the amplification of the fusion transcript. However, performance of nested PCR, which is an additional procedure, may increase the risk of contamination. Although a band of the correct size is obtained in the first PCR analysis in the case of many ASPSSs, nested PCR can be a valuable technique in some cases of ASPS. To ensure that correct-sized bands of ASPSCR1-TFE3 fusion transcript are obtained in the first PCR, it is important to prepare some tubes with progressively increasing quantities of the template in each case. Decrease of the procedure for detection of fusion transcript will lead to a decrease in risk of contamination.

Finally, all our 24 ASPS samples contained type 1 or type 2 fusion variants. If an unknown variant were present in the ASPS samples, such a case would have presented as a negative result by this RT-PCR analysis. Although the distinction between type 1 and type 2 fusion variants was not the aim of this study, our result showed that the frequency of detection of the type 2 variant was twice that of the type 1 variant; this finding does not agree with the comparisons described in previous reports [6,7,19-24]. In Japanese patients with ASPS, the type 2 variant may be the predominant form rather than type 1.

CD147 has been originally identified as a tumor surface protein capable of inducing matrix metalloproteinase expression in fibroblasts [27]. Overexpression of CD147 has been noted in a number of tumors and is known to contribute to tumor invasion and metastasis [13,27]. In the present study, CD147 immunoreactivity was observed not only in ASPS but also in granular cell tumor and clear cell RCC as cytoplasmic granules; furthermore, the cell membranes of 23 of the 24 ASPSSs showed strong immunoreactivity for CD147 (unpublished observations). This finding leads us to conjecture that the expression of CD147 may be related to the early metastasis of ASPS, which presents frequently. The expression of CD147 in ASPS would be valuable as an anticancer target rather than as merely a diagnostic marker.

In the present study, we have demonstrated that the detection of the ASPSCR1-TFE3 fusion transcript is the most sensitive marker for identifying ASPS and is applicable to paraffin-embedded tissues with accuracy superior to immunohistochemical staining for TFE3. Fortunately, we were able to use the tissue blocks with good condition and also able to obtain sufficient RNA for examination of ASPSCR1-TFE3 fusion transcript. Obtaining adequate RNA is probably the most important in detection of the fusion transcript using paraffin-embedded samples. In case of a small biopsy sample or a consultation case in which unstained slides were offered, sufficient RNA may not be extracted, and RT-PCR analysis

may fail. In such a case, fluorescence in situ hybridization (FISH) assay is an effective way to identify the presence of a *TFE3* gene fusion in paraffin-embedded material [17,20]. The results obtained using the RT-PCR method were unexpectedly high in terms of specificity and sensitivity, making it feasible for assays using archival materials from the hospital pathology department and which is expected to be especially useful for studies involving large numbers of cases of more or less rare diseases as well as for the differential diagnosis of tumors with tumor-specific fusion transcripts.

Acknowledgment

The authors thank Dr. Makio Mukai of the Keio University Hospital for providing paraffin-embedded ASPS materials and the relevant clinical information.

References

- [1] Weiss SW, Goldblum JR. Malignant soft tissue tumors of uncertain type. Enzinger and Weiss's soft tissue tumors. 5th ed. Philadelphia, PA: Elsevier Mosby; 2008. p. 1161-220.
- [2] Ordonez NG. Alveolar soft part sarcoma: a review and update. *Adv Anat Pathol* 1999;6:125-39.
- [3] Shipkey FH, Lieberman PH, Foote FW, et al. Ultrastructure of alveolar soft part sarcoma. *Cancer* 1964;17:821-30.
- [4] Lieberman PH, Brennan MF, Kimmel M, et al. Alveolar soft-part sarcoma. A clinicopathologic study of half a century. *Cancer* 1989;63: 1-13.
- [5] Tucker JA. Crystal-deficient alveolar soft part sarcoma. *Ultrastruct Pathol* 1993;17:279-86.
- [6] Kacerovska D, Michal M, Nemcova J, et al. Crystal-deficient alveolar soft-part sarcoma with cutaneous involvement: a case report. *Am J Dermatopathol* 2009;31:272-7.
- [7] Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11; q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. *Oncogene* 2001;20:48-57.
- [8] Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with *TFE3* gene fusions: a sensitive and specific immunohistochemical assay. *Am J Surg Pathol* 2003;27: 750-61.
- [9] Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. *Am J Surg Pathol* 2005;29:1558-75.
- [10] Tanaka M, Kato K, Gomi K, et al. Perivascular epithelioid cell tumor with *SFPQ/PSF-TFE3* gene fusion in a patient with advanced neuroblastoma. *Am J Surg Pathol* 2009;33:1416-20.
- [11] Argani P, Aulmann S, Illei PB, et al. A distinctive subset of PEComas harbors *TFE3* gene fusions. *Am J Surg Pathol* 2010;34:1395-406.
- [12] Ladanyi M, Antonescu CR, Drobnjak M, et al. The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. *Am J Pathol* 2002;160:1215-21.
- [13] Riethdorf S, Reimers N, Assmann V, et al. High incidence of EMMPRIN expression in human tumors. *Int J Cancer* 2006;119: 1800-10.
- [14] Wu J, Brinker DA, Haas M, et al. Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. *Int J Surg Pathol* 2005;13:81-5.
- [15] Amin MB, Patel RM, Oliveira P, et al. Alveolar soft-part sarcoma of the urinary bladder with urethral recurrence: a unique case with

- emphasis on differential diagnoses and diagnostic utility of an immunohistochemical panel including TFE3. *Am J Surg Pathol* 2006;30:1322-5.
- [16] Roma AA, Yang B, Senior ME, et al. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. *Int J Gynecol Pathol* 2005;24:131-5.
- [17] Zhong M, De Angelo P, Osborne L, et al. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. *Am J Surg Pathol* 2010;34:757-66.
- [18] Cataldo KA, Jalal SM, Law ME, et al. Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. *Am J Surg Pathol* 1999;23:1386-92.
- [19] Jun HJ, Lee J, Lim do H, et al. Expression of MET in alveolar soft part sarcoma. *Med Oncol* 2010;27:459-65.
- [20] Aulmann S, Longerich T, Schirmacher P, et al. Detection of the *ASPCRI-TFE3* gene fusion in paraffin-embedded alveolar soft part sarcomas. *Histopathology* 2007;50:881-6.
- [21] Williams A, Bartle G, Kindblom LG, et al. Identification of the *ASPL/TFE3* fusion transcript and immunohistochemical detection of TFE3 in formalin-fixed paraffin-embedded tissue: their role in the diagnosis of alveolar soft part sarcoma (ASPS). Poster Presentation at: USCAP; March 1-7, 2008.
- [22] Bodi I, Gonzalez D, Epaliyange P, et al. Meningeal alveolar soft part sarcoma confirmed by characteristic *ASPCRI-TFE3* fusion. *Neuropathology* 2009;29:460-5.
- [23] Pang LJ, Chang B, Zou H, et al. Alveolar soft part sarcoma: a biomarker diagnostic strategy using TFE3 immunoassay and *ASPL-TFE3* fusion transcripts in paraffin-embedded tumor tissues. *Diagn Mol Pathol* 2008;17:245-52.
- [24] Lazar AJ, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. *Clin Cancer Res* 2007;13:7314-21.
- [25] Liu H, Huang X, Zhang Y, et al. Archival fixed histologic and cytologic specimens including stained and unstained materials are amenable to RT-PCR. *Diagn Mol Pathol* 2002;11:222-7.
- [26] Mizuno T, Nagamura H, Iwamoto KS, et al. RNA from decades-old archival tissue blocks for retrospective studies. *Diagn Mol Pathol* 1998;7:202-8.
- [27] Iacono KT, Brown AL, Greene MI, et al. CD147 immunoglobulin superfamily receptor function and role in pathology. *Exp Mol Pathol* 2007;83:283-95.

Prevalence of human papillomavirus in mobile tongue cancer with particular reference to young patients

Masayuki Kabeya,^{1,2} Reiko Furuta,¹ Kazuyoshi Kawabata,³ Sugata Takahashi² and Yuichi Ishikawa^{1,4}

¹Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo; ²Department of Otolaryngology, Niigata University Faculty of Medicine, Niigata; ³Department of Head and Neck Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

(Received July 7, 2011/Revised October 6, 2011/Accepted October 28, 2011/Accepted manuscript online November 9, 2011/Article first published online December 15, 2011)

The carcinogenic role of human papillomavirus (HPV) in mobile tongue cancer remains unclear because of conflicting results reported in the literature. This disparity is likely to be due to variations in the samples and methods used. Furthermore, despite a tendency for increased prevalence of mobile tongue cancer in young adults, only a few reports specifically in young patients have been published. In the present study on 32 patients, including six in their 20s, we genotyped the prevalence of HPV using a highly sensitive detection tool in fresh-frozen samples from surgical specimens and a novel detection device with electrochemical DNA chip and loop-mediated isothermal amplification. In addition, we confirmed HPV prevalence by *in situ* hybridization and immunohistochemistry for the p16^{INK4a} protein, regarded as a biomarker of HPV-associated cancers. The frequency of 13 genotypes of high-risk HPV was 0/32 (0%), which was further confirmed by *in situ* hybridization. Overexpression of p16^{INK4a} protein was observed in six of the 32 patients (19%), with four (67%) also overexpressing p53. Because there is usually a lack of p53 overexpression in HPV-associated cancer, it is unlikely that p16^{INK4a} protein overexpression is correlated with HPV infection. Consequently, it is unlikely that HPV infection plays an important role in mobile tongue carcinogenesis, in particular in young adults. In addition, our data suggest that the overexpression of p16^{INK4a} protein is not an appropriate biomarker for HPV association in mobile tongue carcinogenesis. (*Cancer Sci* 2012; 103: 161–168)

Human papillomavirus (HPV) is a small DNA virus and more than 130 different types of HPV have been identified based on DNA sequence variations.^(1,2) Human papillomavirus is divided into low-risk and high-risk types, depending on the carcinogenic power.⁽³⁾ It has been conclusively established that more than 99% of uterine cervical cancers are associated with HPV infection.^(2,4) Because HPV-associated cancers may be prevented with vaccination,^(5–7) it is important to determine whether cancer of extracervical organs is associated with HPV infection.^(8,9) Among the head and neck cancers, oropharyngeal cancer, particularly tonsillar cancer, and basal tongue cancer are known to be strongly associated with HPV infection.⁽³⁾ However, the role of HPV in mobile tongue cancer (MTC) remains unclear because of the disparity of results published so far, which have reported HPV infection rates ranging from 0% to 100%.^(10–20) This disparity may be due to differences in the types of samples used and the methods of detection. A recent study has reported an increasing incidence of MTC among young adults.⁽²¹⁾ Thus far, alcohol consumption and heavy cigarette smoking have been suggested as causal factors for MTC.^(11,13) However, it is difficult to explain the high incidence of MTC in young adults simply as a result of accumulated exposure to alcohol and smoking.^(11,21,22) To date, there have been

only a few reports on relationship between MTC (as well as tonsillar cancers) and HPV in young patients.⁽²³⁾

The primary aim of the present study was to determine the prevalence of HPV in MTC using a comprehensive assay series. To that end, we screened rapidly frozen surgical specimens that were subsequently assayed with electrochemical DNA chips (EC chips) and the loop-mediated isothermal amplification (LAMP) method. We confirmed HPV infection using other methodologies, such as *in situ* hybridization (ISH) and immunohistochemistry (IHC) to investigate the overexpression of p16^{INK4a} protein.⁽²⁴⁾ The secondary aim of the study was to elucidate whether overexpression of p16^{INK4a} protein is an appropriate marker HPV infection.

Materials and Methods

Patients. Thirty-two patients presenting with untreated MTC who subsequently underwent surgical resection at the Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), between January 2006 and December 2009 were enrolled in the study. All samples were dissected from a main viable part of each tumor and snap-frozen in liquid nitrogen, typically within 20 min of removal, and stored at -80°C until processing. Histological diagnosis and grading were performed using sections stained with H&E, made from formalin-fixed and paraffin-embedded tissues, based on the World Health Organization (WHO) classification.⁽²⁵⁾ Each tumor was staged according to the Cancer Staging Manual of American Joint Committee on Cancer TNM classification.⁽²⁶⁾ All samples were collected from patients who had provided informed consent, and the study was approved by the Institutional Review Board of the JFCR.

Histological sub-classification. As described previously,^(27,28) squamous cell carcinoma (SCC) of MTC was divided into three groups based on histological features: (i) non-keratinizing (NK) SCC; (ii) keratinizing (K) SCC; and (iii) hybrid SCC. This division is thought to be particularly useful for the analysis of HPV-related SCC because HPV-related tonsillar cancer may derive from the cryptal epithelium, having a more basaloid nature, whereas non-related tonsillar cancer may originate from the surface epithelium.^(29,30) Briefly, NK SCC is defined as forming sheets, nests, or trabeculae with pushing borders and forms comedo-type necrosis. Tumors have ovoid to spindle hyperchromatic cells that lack prominent nucleoli and have indistinct cell borders. In the present study, K SCC was defined as that composed entirely of mature squamous cells with keratinization and intercellular bridges without areas exhibiting NK SCC morphology. Hybrid SCC was defined as SCC having definitive areas with NK SCC morphology but exhibiting squamous maturation

⁴To whom correspondence should be addressed. E-mail: ishikawa@jfcrc.or.jp

in >10% of the tumor. We also used conventional differentiation grading of SCC.

Immunohistochemistry. Formalin-fixed, paraffin-embedded (FFPE) tumor-rich blocks were prepared for p53 and p16^{INK4a} IHC. After deparaffinization, the sections were submerged in either sodium citrate buffer or Tris-EDTA buffer for heat-induced epitope retrieval at 97°C for 40 min. The immunostaining was performed using the EnVision + dextran polymer kit (Dako, Tokyo, Japan) and the CINtec histology kit (MTM Laboratories, Heidelberg, Germany) using a Dako Autostainer (Dako, Glostrup, Denmark). A positive control consisting of an invasive cervical cancer was included. Results were evaluated by one pathologist (YI). "Positive cells" were defined as those exhibiting strong nuclear and cytoplasmic staining for p16^{INK4a} and strong nuclear staining for p53, and we classified tumors in terms of the percentage positive cell as follows: 0, negative; 1+, 1–25% positive cells; 2+, 26–50% positive cells; 3+, 51–75% positive cells; and 4+, >75% positive cells.

In situ hybridization. Additional sections were prepared and deparaffinized for HPV DNA detection using ISH. The ISH was performed using a wide-spectrum HPV biotinylated DNA probe (Dako) for common HPV types and the GenPoint amplification system (Dako) according to the manufacturer's instructions. This wide-spectrum probe targets the genomic DNA of HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, and 52. In each series, a positive control sample, consisting of a tonsillar cancer already identified as HPV positive, was included. Punctate nuclear staining (brown nuclear dots) was considered as positive.

Detection of HPV DNA. Fresh-frozen blocks were added to individual tubes in addition to 200 µL virus standard buffer (comprising 10 mL of 5 M NaCl, 10 mL of 1 M Tris-HCl (pH 7.5), 5 mL of 0.1 M EDTA-2Na (pH 7.5), and 975 mL milliQ water). Each sample was homogenized, followed by the addition of 700 µL virus standard buffer, 100 µL of 10% SDS, and 25 µL of 25 mg/mL proteinase K solution. Samples were incubated overnight at 37°C. After digestion, DNA purification was performed by phenol-chloroform extraction and ethanol precipitation. The quantity and quality of the DNA were assessed by spectrophotometry and electrophoresis on a 1% agarose gel. The DNA solutions were stored at 4°C.

Human papillomavirus detection and genotyping were performed using an HPV DNA genotyping system. The DNA extracted from each sample was incubated at 95°C for 5 min and then cooled immediately on ice. A 1-µL aliquot of the DNA was added to each of the six LAMP tubes, containing 24 µL LAMP reagent and specific primers for the different types of HPV. The tubes were incubated at 65°C for 90 min, then at 80°C for 5 min, and the cooled immediately on ice. A 10-µL aliquot of the amplified products from each tube was mixed with 6 µL hybridization buffer (saline citrate solution), and 50 µL mixed LAMP product was applied to an EC chip, which uses novel current detection technology (CLINICHP HPV; Sekisui-medical, Tokyo, Japan). The EC chip was placed in Genalyzer GLH-2C601 (Toshiba Hokuto Electronics, Asahikawa, Japan), which is an instrument designed to measure electrochemical signals from the EC chip. A positive control was included in each series, consisting of an invasive cervical cancer. The results were evaluated automatically. The principle of measurement was as follows. Thirteen DNA types (type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) of high-risk HPV were amplified using the LAMP method with 13 primers that amplify HPV DNA in a type-specific manner. This HPV DNA genotyping assay targets the L1 open reading frames, conserved among most of the HPV genomes. The DNA probes for the target genes are fixed on the electrodes of the EC chip. When HPV DNA extracted from samples is amplified and introduced to the EC chip, it reacts and binds only with the probe with the complementary sequence. Subsequently, when an intercalator (i.e.

labeling reagent for the double-strand structure) is added, it only combines with the DNA that has reacted and current flows only between the bound intercalator and the EC chip electrode. The sequence of the sample DNA is determined by detecting this current. The criteria used to evaluate the samples were as follows. Positive samples were scored where the current level of the test specimen was higher than that of the average for the negative control by ≥10 nA. Negative samples were scored where the difference in current levels between the test specimen and the average of the negative control was within 10 nA. Invalid samples were scored when the average current level of the negative control was >45 nA. All genotypes were detected at a 100% positive at HPV DNA 250 copies per 1 µL. The HPV genotypes determined by this HPV DNA genotyping system for 244 test clinical samples were compared with direct PCR sequencing using specific primers for 13 genotypes. The concordance rate for HPV genotyping was 95.5% (233/244).

Statistical analysis. Statistical analyses for a correlation between age groups, younger (20–39 years) and older patients (40–90 years), or immunoreactivity and the clinical outcome were performed using Fisher's exact test. Differences in disease-free survival and overall survival between younger (20–39 years) and older patients (40–90 years) were evaluated using the Kaplan-Meier method, starting from the date of surgery. Survival curves was compared using the log-rank test. *P* < 0.05 was considered significant.

Results

Table 1 lists the characteristics of the 32 patients in the present study. Twenty-nine patients (91%) were male and three (9%) were female. The age of the patients ranged between 21 and 90 years, with a median age 55 years. Ten patients (31%), including six who were in their 20s, were younger than 40 years. The mean follow-up time was 26.1 months, with a maximum of 53 months. One of 32 patients was diagnosed histologically as having spindle cell carcinoma, whereas the others were all diagnosed with standard SCC. The patient with spindle cell carcinoma was a 55-year-old male smoker who also had the heaviest alcohol consumption per day among the 32 patients. The spindle cell carcinoma recurred in 10 months and the patient died 23 months after surgery. Most patients had well-differentiated tumors, but three had moderately (26-, 44-, and 76-year-old men) and two had poorly (31- and 38-year-old men) differentiated tumors. Although the three patients with moderately differentiated tumors had no recurrence, tumors in the two patients with poorly differentiated tumors recurred: one

Table 1. Patient and tumor characteristics

Sex (n)	
Male/female	29/3
Age (years)	
Median (range)	55 (21–90)
Tumor histology (n)	
SCC/spindle cell carcinoma	31/1
Histological grade of SCC (n)	
Well/moderately/poorly differentiated	26/3/2
Pathological stage* (n)	
I+II/III+IV	8/22
Alcohol consumption (n)	
Yes/no/incidental	11/10/11
Cigarette exposure (n)	
Yes/no/former smoker	12/12/8

*Excluding two patients in whom regional lymph nodes could not be assessed. Alcohol consumption categorized as "yes" indicated daily, whereas that categorized as "incidental" indicated social drinkers. SCC, squamous cell carcinoma.

Table 2. Clinicopathologic features, results of immunohistochemistry (p16^{INK4a} and p53 status), ISH, human papillomavirus DNA detection, and clinical outcome

Patient no.	Age (years)	Sex	pTN	Histologic features*	p16 ^{INK4A} expression†	p53 expression†	ISH	GS‡	Outcome
1	21	M	pT2N2b	Hybrid SCC	4+	4+	-	-	Death
2	25	M	pT1N0	K SCC	-	4+	-	-	Death
3	26	M	pT3N2b	K SCC	3+	4+	-	-	No recurrence
4	27	M	pT3N1	K SCC	-	3+	-	-	Death
5	28	M	pT2N0	K SCC	-	3+	-	-	Death
6	28	M	pT4aN2b	K SCC	-	4+	-	-	No recurrence
7	31	M	pT2N2b	Hybrid SCC	-	-	-	-	Death
8	33	M	pT4aN2b	Hybrid SCC	-	4+	-	-	Death
9	35	M	pT2N2b	Hybrid SCC	-	4+	-	-	Death
10	38	M	pT1N0	Hybrid SCC	-	-	-	-	Recurrence, alive
11	44	M	pT4aN0	Hybrid SCC	-	-	-	-	No recurrence
12	47	M	pT2N2	K SCC	-	-	-	-	No recurrence
13	48	M	pT2N0	K SCC	2+	1+	-	-	No recurrence
14	49	F	pT3N1	Hybrid SCC	-	4+	-	-	No recurrence
15	51	M	pT3N0	K SCC	-	-	-	-	No recurrence
16	55	M	pT3N0	Spindle CC	-	4+	-	-	Death
17	55	M	pT2N0	K SCC	-	-	-	-	No recurrence
18	57	M	pT1N0	K SCC	-	-	-	-	No recurrence
19	59	M	pT2N0	K SCC	1+	1+	-	-	No recurrence
20	60	F	pT3N2c	Hybrid SCC	-	3+	-	-	Death
21	64	M	pT2N2b	K SCC	-	3+	-	-	DOD
22	68	M	pT2N2b	K SCC	-	2+	-	-	DOD
23	69	M	pT3N0	K SCC	-	-	-	-	No recurrence
24	71	M	pT2NX	K SCC	4+	-	-	-	No recurrence
25	72	M	pT2N1	K SCC	1+	-	-	-	No recurrence
26	76	M	pT2N0	Hybrid SCC	-	-	-	-	No recurrence
27	77	M	pT4aN2b	Hybrid SCC	-	4+	-	-	Death
28	78	M	pT3N2b	K SCC	-	3+	-	-	Death
29	79	M	pT2N2b	K SCC	-	1+	-	-	Death
30	80	F	pT3N2b	K SCC	-	4+	-	-	Death
31	85	M	pT3N2b	K SCC	-	-	-	-	Death
32	90	M	pT2NX	K SCC	-	-	-	-	Death

*Tumors were classified into three types histologically: (i) keratinizing squamous cell carcinoma (K SCC); (ii) non-keratinizing squamous cell carcinoma (NK SCC); and (iii) mainly NK SCC but with areas of squamous maturation (Hybrid SCC). †The percentage of positive-stained cells were scored as follows: 0, negative; 1+, 1–25% positive cells; 2+, 26–50% positive cells; 3+, 51–75% positive cells; and 4+, >75% positive cells. Note, p16^{INK4A}-positive cells were those in which both the nucleus and cytoplasm were stained, whereas p53-positive cells exhibited nuclear staining only. ‡The genotyping system (GS) used in the present study is a novel tool to detect 13 types of high-risk human papillomavirus (HPV) strains using electrochemical technology and loop-mediated isothermal amplification (LAMP). DOD; death from other disease. IHC; *in situ* hybridization, Spindle CC; spindle cell carcinoma.

within 7 months, with the patient dying 30 months after surgery, and the other within 8 months. This second patient is still alive 40 months after surgery, although at a terminal stage.

Regarding pathologic stages, eight patients (27%) were in early Stages I/II, 22 (73%) were in advanced Stages III/IV, and two were unstaged because their lymph nodes were not examined. Of the eight patients in early Stages I/II, three (38%) were younger and five (62%) were older than 40 years of age. Two (67%) of the three younger patients in early Stages I/II had local recurrence, whereas none (0%) of the five older patients had any recurrence ($P = 0.107$). Of the 22 patients with advanced Stages III/IV, seven (32%) were younger and 15 (68%) were older than 40 years of age. The percentage of patients with an unfavorable outcome was 72% (5/7) in the younger age group and 54% (7/13) in the older age group ($P = 0.392$). The remaining two patients in whom staging was not performed died from other diseases. Therefore, there were no significant differences in the prognosis between younger (<40 years) and older (>40 years) patients.

Of the 32 patients, 12 (38%) were daily smokers, eight (24%) were past smokers, and 12 (38%) were life-time non-smokers. The mean cumulative smoking cigarette volume was 31.6 pack-

years for the 12 daily smokers and 11.9 for the eight past-smokers. Only 11 of the 32 patients (34%) in the present study were drinkers. In addition, seven of the 32 patients (22%) were neither smokers nor consumers of alcohol and one of these seven was in his 20s.

Table 2 gives the clinicopathological features and results of IHC (p16^{INK4a} and p53), ISH, HPV DNA detection and genotyping analyses. The 32 tumors were classified histologically as one spindle cell carcinoma and 31 SCCs. Of the 31 SCCs, 21 (68%) were classified as K SCC (Fig. 1a), none (0%) was found to be an NK SCC, and 10 (32%) were determined to be hybrid SCC (Fig. 1b). Overexpression of p16^{INK4a} was noted in six of 32 patients (19%; Fig. 2a). The grading of the p16^{INK4a}-positive tumors was as follows: two were 1+, one was 2+, one was 3+, and two were 4+. Two of three tumors (67%) with strong reactivity (3+ or 4+) were in patients who were aged in their 20s. Only one of six patients (17%) with overexpression of p16^{INK4a} experienced local recurrence and died, whereas 14 of 26 patients (54%) without p16^{INK4a} overexpression died, indicating a prognostic value of p16^{INK4a}, although the difference failed to reach statistical significance in the current sample set ($P = 0.116$). Overexpression of p53 was noted in 19 of 32 tumors (59%;




Fig. 1. Histological features (H&E stain). (a) Squamous cell carcinoma (SCC) composed entirely of keratinizing malignant cells and (b) SCC composed mainly of non-keratinizing malignant cells but also exhibiting partly formed squamous maturation (hybrid SCC). Scale lines, 1.00 mm (a); 400 μ m (b).

Fig. 2b). Specifically, 13 tumors were not stained, four were weakly stained (three 1+ tumors and one in 2+ tumor), and 15 were strongly stained (five 3+ tumors and ten 4+ tumors). Eight of 10 patients (80%) who were <40 years of age were found to overexpress p53. Eleven of the 15 patients (73%) with strong p53 overexpression died of MTC, one from another disease; in contrast of the 17 patients with no or only weak p53 expression, only four (24%) died of MTC, one from another disease. All other patients survived. Therefore, patients with strong p53 overexpression had a significantly less favorable prognosis than those with weak or no p53 expression ($P < 0.01$). With ISH using the wide-spectrum probes against carcinogenic HPV DNA, none of the samples in our series showed the punctate pattern, correlated with viral DNA integration (Fig. 2c). Consequently, although we used two carcinogenic HPV DNA detection methods (i.e. ISH and the novel HPV DNA genotyping system) and they worked well for a positive control case with tonsillar and cervical cancer (Figs 2d and 3b), all samples of MTC were negative (Figs 2c and 3a).

The 3-year disease-free and overall survival rates were 48% and 50%, respectively. The prognosis for younger patients (20–39 years) was less unfavorable than that for older (40–90 years)

patients in terms of both disease-free and overall survival. A significant difference was found between these two age groups in terms of disease-free survival ($P = 0.027$), but not for overall survival ($P = 0.102$; Fig. 4).

Discussion

It is important to determine whether extracervical cancers are associated with HPV because these cancers may be preventable by HPV vaccination. Of the extracervical sites, tumors in the oral cavity, oropharynx, esophagus, penis and anus are possibly associated with HPV because of its route of infection^(31–33) and, indeed, tumors in these sites exhibit morphological similarities.^(16,30) Of the head and neck cancers, oropharyngeal cancer is related to HPV, as is tonsillar cancer in particular, with detection rates of HPV16, HPV18, and/or HPV33 reported in the range of 21–100%.^(19,34–36) Interestingly, HPV-positive tumors have been reported to respond better to chemoradiotherapy than HPV-negative tumors and survival is longer in patients with HPV-positive tumors than those with -negative tumors.^(23,37–41) Although the importance of carcinogenic HPV infection is well recognized for diagnostic and therapeutic strategies in tonsillar cancer, the prevalence of HPV in MTC (adjacent to tonsillar cancer) remains uncertain. In the present study, we evaluated the prevalence of carcinogenic HPV infection and investigated the correlation between p16^{INK4a} protein expression and HPV. We found that there was no evidence of carcinogenic HPV infection in MTC and that the p16^{INK4a} protein was not an appropriate marker of HPV infection.

Although the possibility that HPV is relevant to MTC has been suggested, there are no reliable prevalence data supporting this assertion. This may be due mainly to the diverse target groups or methodologies used by different studies. In fact, some previous studies have classified MTC as an oral cancers,^(14,42) which is too broad a classification to allow causal agents to be specified. Furthermore, different studies have used different experimental procedures: ISH, Southern blot hybridization, IHC and PCR have been used for detection; brush, biopsy, and surgery have been used for sampling; and fresh-frozen or FFPE tissue blocks have been used for storage.^(43,44) Fresh-frozen materials seem to provide higher detection rates than FFPE samples, probably because of target DNA degeneration following formalin fixation; furthermore, PCR methods appear to be more sensitive than others.⁽⁴⁵⁾ Using FFPE samples may result in the possible contamination of carcinogenic HPV DNA at the time of sectioning.⁽¹³⁾ Therefore, in the present study, we chose to use fresh-frozen materials from surgical specimens to avoid both DNA degeneration and contamination. In addition, the LAMP method used in the present study is reportedly equivalent to, or even more sensitive than, PCR.^(46,47) We also used ISH for additional confirmation of HPV DNA. Thus, we tried to achieve higher sensitivity and higher accuracy than in previous studies.

In addition to differences in the methodologies used in previous studies, the wide range in the prevalence of HPV reported in different studies may be ascribed to variations in the nature of HPV-associated cancers. For example, a geographic heterogeneity of HPV-associated cancers has been reported. In India and Southeast Asia, oral cancer is a predominant malignancy, accounting for up to 50% of all cancers.⁽¹⁰⁾ Similarly, HPV prevalence in oropharyngeal cancer is significantly higher in North America and Asia than in Europe.⁽⁸⁾ Another factor that may impact on the apparent prevalence of HPV is the time period/s examined. For example, Okinawa, a subtropical island in south-west Japan, the prevalence of HPV in SCC of the lung we found to decrease significantly over a relatively short period of time, from 68% in 1995, to 35% in 1996, 23% in 1997, and 24% in 1998.⁽⁴⁸⁾ In the present study, all patients examined were from mainland Japan, a region with a lower prevalence of HPV




Fig. 2. (a–c) Immunohistochemical staining for p16^{INK4A} (a) and p53 (b), and *in situ* hybridization (ISH) findings (c) for Patient 1 (see Table 2). (d) Tonsillar cancer positive control for ISH (brown indicates nuclear staining). (a) Strong nuclear and cytoplasmic staining was seen for p16^{INK4A} (i.e. >75% positive cells) and (b) strong nuclear staining was seen for p53 (also >75% positive cells). (c) The tumor was negative by ISH. Scale lines, 200 μ m (a,b); 100 μ m (c,d).

infection than Okinawa. Based on the findings of the previous studies discussed above, our results of no HPV infection in MTC may be explained, in part, by the facts that all our patients were from a region with low HPV infection and that the present study was performed using recent cases (2006–2009).

Characteristic histopathology of HPV-related cancers has been reported, with differentiation grades appearing to differ depending on the site. For example, HPV-related SCC in the lung are mostly well differentiated,⁽⁴⁸⁾ half of all uterine cervical cancers are moderately differentiated,^(49,50) and tonsillar SCC are poorly differentiated.^(29,30) Unfortunately, the relatively low number of cases in the present study means that we did not have a sufficiently wide enough spectrum of differentiation (e.g. we only had two cases of poorly differentiated tumors and no NK SCC cases) and so we cannot draw any conclusions about the histopathology of HPV-related MTC. However, it should be kept in mind that the subclassification of SCC used in the present study was derived originally from 89 tonsillar cancers and that there is a basic histological difference between the mobile tongue and the tonsil. In fact, the mobile tongue is covered by keratinized squamous epithelium, whereas the tonsil is coated with stratified, non-keratinized squamous epithelium. Thus, a subclassification system based

on squamous cell maturation (i.e. keratinization) may not be suitable for classifying MTC.

Sexual behavior may be another factor affecting the prevalence of HPV. A higher number of lifetime sexual partners and engaging in oral sex are principal risk factors for exposure to HPV. In fact, several studies have reported increased risks of oral and oropharyngeal cancers among individuals with a high number of sexual partners.^(9,42,43,51,52) Unfortunately, we cannot comment on the relationship between HPV infection in MTC in terms of sexual behavior in the present study because there are no data available. In terms of the impact of sexual behavior, notably that oral sex is a predominant cause of increased rates of MTC, a possible drawback of the present study is that only three of the 32 patients were women. There may be a greater correlation between MTC and HPV in women than in men because the issue of oral sex may be more relevant in the case of women.

Overexpression (1+ to 4+) of p16^{INK4a} protein was observed in six of 32 patients (19%) of MTC. Integration of HPV to host cells leads to increased expression of oncogenes *E6* and *E7*. The HPV *E6* and *E7* proteins bind and functionally inhibit p53 and retinoblastoma protein (pRb), respectively, and the functional inactivation of pRb by *E7* leads to upregulation of p16^{INK4a} protein as a result of the loss of negative feedback control.^(53,54)




Fig. 3. Presence of high-risk human papillomavirus (HPV), as determined using a novel HPV DNA genotyping system with an electrochemical DNA chip and loop-mediated isothermal amplification (LAMP). Lane numbers correspond to HPV genotypes. PC, positive control; NC, negative control. (a) Patient 1 (see Table 2) was negative for all HPV genotypes. (b) A positive control sample (HPV genotype 18, cervical cancer, DNA extracted from paraffin-embedded block).

Thus, both overexpression of p16^{INK4a} protein and lack of expression of p53 are usually evidence of an HPV-associated cancer.^(28,55,56) However, in the present study, four of six tumors (67%) with p16^{INK4a} overexpression also exhibited p53 overexpression. This suggests that the p16^{INK4a} overexpression in these tumors bears little relation to HPV. It is true that overexpression of p16^{INK4a} protein is a biomarker for cervical or tonsillar cancer arising from carcinogenic HPV infection,^(30,33,57,58) but this is not the case for MTC.




Fig. 4. Kaplan-Meier survival curves for (a) disease-free survival and (b) overall survival in younger (20–39 years) and older (40–90 years) patients. Both disease-free and overall survival analyses indicated a tendency for a less favorable prognosis in younger compared with older patients. However, the difference only reached statistical significance in the case of disease-free survival (log-rank test).

The incidence of MTC among young adults is reported to be increasing, but this cannot be explained by ordinary carcinogens for oral cancer, such as smoking and alcohol consumption, because young people must have less cumulative exposure to carcinogens than older people.^(21,59,60) It has been suggested that the increased HPV infection in industrialized countries was due, in part, to changing sexual behavior and an increase in oral sex.^(61,62) This may be a cause of increased MTC, but are only few studies have investigated MTC in young patients, especially those in their 20s (Table 3). In the present study there were no HPV-positive cases in the six patients aged in their 20s or in the 10 young adults (20–39 years old). On the basis of these results, it is unlikely that HPV infection is a cause of increased MTC

Table 3. Human papillomavirus prevalence in mobile tongue cancer among young patients (<45 years of age)

References	Detection technique	Age (years)	Detection rate	Sample storage
Cruz <i>et al.</i> ⁽¹⁶⁾	PCR	37, 39	2/2	FF
Liang <i>et al.</i> ⁽¹¹⁾	PCR	<45	1/8	FF
O'Regan <i>et al.</i> ⁽²⁰⁾	PCR	31, 33, 33, 37, 39, 39	HPV16 DNA 2/6 HPV16 E6/E7 mRNA 0/6	FF+PE
Cao <i>et al.</i> ⁽¹⁸⁾	PCR	31, 38, 40, 42, 44	3/5	PE
Premoli-de-Percoco <i>et al.</i> ⁽¹⁵⁾	PCR	29, 31, 32, 35, 40	5/5	FF
Siebers <i>et al.</i> ⁽¹⁴⁾	ISH, PCR	23, 37	0/2	PE
Present study	ISH, GS*	21, 25, 26, 27, 28, 28, 31, 33, 35, 38, 44	0/11	FF

*The genotyping system (GS) used in the present study is a novel tool to detect 13 types of high-risk human papillomavirus (HPV) strains using electrochemical technology and loop-mediated isothermal amplification (LAMP). FF, fresh-frozen; PE, paraffin-embedded; ISH, *in situ* hybridization; PCR, polymerase chain reaction.

among the young. Thus, the cause of the increasing incidence of MTC among young people remains unclear.

Acknowledgments

The authors thank Ms Reimi Asaka (Division of Pathology, JFCR Cancer Institute) for technical assistance. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education,

Culture, Sports, Science and Technology, Japan (18014027), from the Japan Society for the Promotion of Science (20390105), grants from the Ministry of Health, Labour and Welfare (19–12), the Japan Science and Technology Agency, and the Smoking Research Foundation.

Disclosure Statement

The authors have no conflicts of interest.

References

- 1 Jo S, Juhasz A, Zhang K *et al*. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinoma treated in a prospective Phase II clinical trial. *Anticancer Res* 2009; **29**: 1467–74.
- 2 Machado J, Reis PP, Zhang T *et al*. Low prevalence of human papillomavirus in oral cavity carcinomas. *Head Neck Oncol* 2010; **2**: 6.
- 3 El-Mofty SK. Human papillomavirus (HPV) related carcinomas of the upper aerodigestive tract. *Head Neck Pathol* 2007; **1**: 181–5.
- 4 Walboomers JM, Jacobs MV, Manos MM *et al*. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999; **189**: 12–9.
- 5 Harper DM, Franco EL, Wheeler C *et al*. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. *Lancet* 2004; **364**: 1757–65.
- 6 Michel KB, zur Hausen H. HPV vaccine for all. *Lancet* 2009; **374**: 268–70.
- 7 Paavonen J, Naud P, Salmemon J *et al*. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 2009; **374**: 301–14.
- 8 Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 467–75.
- 9 D'Souza G, Kreimer AR, Viscidi R *et al*. Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* 2007; **356**: 1944–56.
- 10 Bouda M, Gorgoulis VG, Kastrinakis NG *et al*. "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. *Mod Pathol* 2000; **13**: 644–53.
- 11 Liang XH, Lewis J, Foote R, Smith D, Kademani D. Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. *J Oral Maxillofac Surg* 2008; **66**: 1875–80.
- 12 Matzow T, Boysen M, Kalantari M, Johansson B, Haqmar B. Low detection rate of HPV in oral and laryngeal carcinomas. *Acta Oncol* 1998; **37**: 73–6.
- 13 Kansky AA, Poljak M, Seme K *et al*. Human papillomavirus DNA in oral squamous cell carcinomas and normal oral mucosa. *Acta Virol* 2003; **47**: 11–6.
- 14 Siebers TJ, Merckx MA, Slootweg PJ, Melchers WJ, van Cleef P, de Wilde PC. No high-risk HPV detected in SCC of the oral tongue in the absolute absence of tobacco and alcohol: a case study of seven patients. *Oral Maxillofac Surg* 2008; **12**: 185–8.
- 15 Premoli-de-Percoco G, Ramirez JL. High risk human papillomavirus in oral squamous carcinoma: evidence of risk factors in a Venezuelan rural population. Preliminary report. *J Oral Pathol* 2001; **30**: 355–61.
- 16 Cruz IB, Snijders PJ, Steenbergen RD *et al*. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. *Eur J Cancer B Oral Oncol* 1996; **32**: 55–62.
- 17 Mork J, Lie AK, Glatte E *et al*. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. *N Engl J Med* 2001; **344**: 1125–31.
- 18 Cao J, Zhang ZY, Patima, Zhang YX, Chen WT. Human papillomavirus infection and p53 alteration in oral squamous cell carcinoma. *Chin J Dent Res* 2000; **3**: 44–9.
- 19 Dahlgren L, Dahlstrand HM, Lindquist D *et al*. Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. *Int J Cancer* 2004; **112**: 1015–9.
- 20 O'Regan EM, Toner ME, Finn SP *et al*. p16^{INK4A} genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. *Hum Pathol* 2008; **39**: 452–8.
- 21 Salem A. Dismissing links between HPV and aggressive tongue cancer in young patients. *Ann Oncol* 2010; **21**: 13–7.
- 22 Chitapanarux I, Lorvidhaya V, Sittitirai P *et al*. Oral cavity cancers at a young age: analysis of patient, tumor and treatment characteristics in Chiang Mai University Hospital. *Oral Oncol* 2006; **42**: 83–8.
- 23 Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. *Cancer* 2005; **103**: 1843–9.
- 24 Shinghi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. *Cancer* 2010; **116**: 2166–73.
- 25 Bernes L, Eveson JW, Reichart P, Sidransky D, eds. *World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumors*. Lyon: IARC, 2005; 163–208.
- 26 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. *American Joint Committee on Cancer. Cancer Staging Manual*, 7th edn. Chicago: Springer Publishers, 2010; 29–40.
- 27 Lewis JS Jr, Thorstad WL, Chernock RD *et al*. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. *Am J Surg Pathol* 2010; **34**: 1088–96.
- 28 Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS Jr. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. *Head Neck Pathol* 2009; **3**: 186–94.
- 29 Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. *Clin Cancer Res* 2005; **11**: 5694–9.
- 30 Kim SH, Koo BS, Kang S *et al*. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. *Int J Cancer* 2007; **120**: 1418–25.
- 31 McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses. *Virus Res* 2009; **143**: 195–208.
- 32 Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. *Clin Cancer Res* 2009; **15**: 6758–62.
- 33 Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: role of E6 and E7 proteins. *Cancer Sci* 2007; **98**: 1505–11.
- 34 Syrjänen S. HPV infections and tonsillar carcinoma. *J Clin Pathol* 2004; **57**: 449–55.
- 35 Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. *Clin Cancer Res* 2002; **8**: 3187–92.
- 36 Nasman A, Attner P, Hammarstedt L *et al*. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? *Int J Cancer* 2009; **125**: 362–6.
- 37 Fakhry C, Westra WH, Li S *et al*. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J Natl Cancer Inst* 2008; **100**: 261–9.
- 38 Gillison ML, Koch WM, Capone RB *et al*. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000; **92**: 709–20.
- 39 Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. *Cancer* 2001; **92**: 805–13.
- 40 Ritchie JM, Smith EM, Summersgill KF *et al*. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. *Int J Cancer* 2003; **104**: 336–44.
- 41 Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. *Int J Cancer* 2007; **121**: 1813–20.
- 42 Adelstein DJ, Ridge JA, Gillison ML *et al*. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. *Head Neck* 2009; **31**: 1393–422.
- 43 Goon PK, Stanley MA, Ebmeyer J *et al*. HPV & head and neck cancer: a descriptive update. *Head Neck Oncol* 2009; **1**: 36.
- 44 Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. *Clin Otolaryngol* 2006; **31**: 259–66.
- 45 Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. *Crit Rev Oral Biol Med* 2004; **15**: 188–96.

- 46 Takagi H, Itoh M, Islam MZ *et al.* Sensitive, specific, and rapid detection of *Leishmania donovani* DNA by loop-mediated isothermal amplification. *Am J Trop Med Hyg* 2009; **81**: 578–82.
- 47 Notoi T, Okayama H, Masubuchi H *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* 2010; **28**: E63.
- 48 Miyagi J, Tsuchioka K, Kinjo T, Iwamasa T, Hirayasu T. Recent striking changes in histological differentiation and rate of human papillomavirus infection in squamous cell carcinoma of the lung in Okinawa, a subtropical island in southern Japan. *J Clin Pathol* 2000; **53**: 676–84.
- 49 Sellors JW, Sankaranarayanan R. *Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginners' Manual*. Lyon: IARC, 2003; 21–8.
- 50 Kid EA, Spencer CR, Huettner PC *et al.* Cervical cancer histology and tumor differentiation affect ¹⁸F-fluorodeoxyglucose uptake. *Cancer* 2009; **115**: 3548–54.
- 51 Gillison M, D'Souza G, Westra W *et al.* Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. *J Natl Cancer Inst* 2008; **100**: 407–20.
- 52 Schwartz SM, Darling JR, Doody DR *et al.* Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. *J Natl Cancer Inst* 1998; **90**: 1626–36.
- 53 Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. *Infect Agent Cancer* 2010; **5**: 4.
- 54 Andl T, Kahn T, Pfuhl A *et al.* Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. *Cancer Res* 1998; **58**: 5–13.
- 55 Weinberger PM, Yu Z, Haffty BG *et al.* Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. *J Clin Oncol* 2006; **24**: 736–47.
- 56 Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. *Proc Natl Acad Sci U S A* 2006; **103**: 14.
- 57 Klaes R, Friedrich T, Spitkovsky D *et al.* Overexpression of p16^{INK4A} as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. *Int J Cancer* 2001; **92**: 276–84.
- 58 Klussmann JP, Gultekin E, Weissenborn SJ *et al.* Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. *Am J Pathol* 2003; **162**: 747–53.
- 59 Atual S, Grenman R, Laippala P, Syrjanen S. Cancer of the tongue in patients younger than 40 years. *Arch Otolaryngol Head Neck Surg* 1996; **122**: 1313–9.
- 60 Myers JN, Elkins T, Roberts D, Byers RM. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. *Otolaryngol Head Neck Surg* 2000; **122**: 44–51.
- 61 D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. *J Infect Dis* 2009; **199**: 1263–9.
- 62 Nguyen NP, Chi A, Nguyen LM, Ly BH, Karlsson U, Vinh-Hung V. Human papillomavirus-associated oropharyngeal cancer: a new clinical entity. *Q J Med* 2010; **103**: 229–36.

Diverse Fusion Patterns and Heterogeneous Clinicopathologic Features of Renal Cell Carcinoma With t(6;11) Translocation

Kentaro Inamura, MD, PhD,* Mutsunori Fujiwara, MD, PhD,† Yuki Togashi, MS,*
Kimie Nomura,* Hiroyuki Mukai, BSc,‡ Yasuhisa Fujii, MD, PhD,§ Shinya Yamamoto, MD, PhD,§
Junji Yonese, MD, PhD,§ Iwao Fukui, MD, PhD,§ and Yuichi Ishikawa, MD, PhD*

Abstract: Renal cell carcinoma (RCC) with t(6;11) translocation, involving the transcription factor EB (*TFEB*) and *Alpha*, also known as *MALAT1*, (TFEB RCC), is extremely rare, with only 20 cases reported to date. It may be frequently misdiagnosed because of a lack of established characteristics. TFEB RCCs are predominantly seen in younger patients and are generally indolent, with only 2 cases of metastasis. Genetic analysis has been limited, showing break points upstream of *TFEB* exon 3, yielding only a single transcript. We examined 3 new adult Japanese TFEB RCC cases by means of precise clinicopathologic, immunohistochemical, cytogenetic, and molecular analyses and compared them with 200 ordinary RCCs. A 57-year-old man was the oldest patient with TFEB RCC at the time of this study. Although the tumor had histology typical of translocation RCC, its fusion points were different between the genomic and transcript coordinates. A 37-year-old man had an aggressive course resulting in death. The tumor had 2 variants of messenger ribonucleic acid. A 47-year-old man showed borderline histologic and immunohistochemical features between TFEB RCC and chromophobe-type RCC. The tumor had a fusion point in *TFEB* exon 4, downstream of the wild-type ATG in exon 3. Nuclear expression of the TFEB protein was detected, and a Western blotting analysis identified a protein similar in size to the wild-type TFEB protein. Immunohistochemistry is useful for the diagnosis of these tumors, and TFEB RCCs have heterogeneous clinicopathologic features and more diverse fusion patterns than previously thought, requiring attention to polymerase chain reaction experiments for diagnosis. Our study will contribute to the correct diagnosis of TFEB RCC.

Key Words: renal cell carcinoma, translocation, TFEB, *MALAT1*
(*Am J Surg Pathol* 2012;36:35–42)

From the *Division of Pathology, The Cancer Institute; §Department of Urology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research; †Department of Clinical Pathology, Japanese Red Cross Medical Center; and ‡FML Laboratory, Tokyo, Japan.

Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Yuichi Ishikawa, MD, PhD, Division of Pathology, The JFCR Cancer Institute, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan (e-mail: ishikawa@jfc.or.jp).

Copyright © 2011 by Lippincott Williams & Wilkins

Renal cell carcinoma (RCC) with t(6;11) translocation, involving the transcription factor EB (*TFEB*), is an extremely rare neoplasm, with only 20 cases reported to date.^{1–3,5,6,8,9,11–13,15–17} The reason why so few cases have been reported to date is that *TFEB* translocation renal cell carcinoma (TFEB RCC) is a recently recognized tumor entity.^{1,2} Owing to its rarity, TFEB RCC can be easily misdiagnosed as another subtype of RCC or epithelioid angiomyolipoma, especially as a clear cell variant. According to the available clinical histories, TFEB RCC is predominantly seen in young patients and is generally indolent, with only 2 cases of metastases.^{5,12} Genetically, TFEB RCC has been characterized by the fusion of the 5' portion of *Alpha*, also known as *MALAT1* (Genbank accession number AF203815), an intronless gene mapped at 11q12, with *TFEB* at 6p21. According to the few available data from TFEB RCC cases, *Alpha* fusion points have been scattered in the 1.2-kb break point cluster region (bcr), and *TFEB* fusion points have been scattered in the 289-bp bcr, numbered from the 5' end of exon 3 of *TFEB*. All of the previously reported TFEB RCCs showed break points upstream of the *TFEB* exon 3, which led to identical genomic and transcript coordinates, yielding only a single transcript.

To elucidate the genetic and clinicopathologic features of this rare tumor entity, we examined 3 new adult Japanese TFEB RCC cases by means of precise clinicopathologic, cytogenetic, and molecular analyses and demonstrated heterogeneous clinicopathologic features and more diverse fusion patterns than previously thought to exist for this neoplasm.

MATERIALS AND METHODS

Patients, Tissues, and Tissue Microarray Construction

This study was conducted using clinical samples from 3 TFEB RCC cases (cases 1 to 3) and from 200 cases of common subtypes of RCCs (165 clear cell type, 23 chromophobe type, and 12 papillary type) for tumor tissue arrays and immunohistochemistry (IHC). Background data of the 3 TFEB RCC patients were collected from clinical records. All specimens were collected with